University of Miami
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Miami sits in the top decile of US sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count).
University of Miami: 721 sponsored US clinical trials, 145 recruiting.
University of Miami sponsors 721 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 430 completed. 79 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 10 trials.
Top-decile sponsor footprint
University of Miami ranks in the top decile of sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
430 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
721 total, page 15 of 15
Preterm Infants' Weight Gain Following Massage Therapy
NCT00029198
Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors
NCT00945828
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
NCT00685061
Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers
NCT00253682
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
NCT00681343
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
NCT00448643
Effects of Human Leptin Replacement
NCT00657605
Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
NCT00315614
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
NCT00533442
Family-based and Adolescent Residential Drug Treatment
NCT01737632
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT00006021
Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation
NCT00681213
Tube Versus Trabeculectomy (TVT) Study
NCT00306852
Facilitating Positive Adaptation to Breast Cancer
NCT01422551
Cognitive Behavioral Stress Management (CBSM) & Prostate Cancer
NCT05486754
Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
NCT00002533
Stroke Incidence and Risk Factors in a Tri-ethnic Region
NCT03266952
Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002492
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
NCT00003582
5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris
NCT00714454
A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
NCT00002270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 86 |
| Phase 3 | 18 |
| Phase 4 | 61 |
Therapeutic Areas
What is open in the University of Miami pipeline
145 recruiting of 721 indexed (20% open); 430 completed (60%).
Phase mix: 79 late (III/IV) vs 134 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Miami: open-pipeline peers nationwide
Peers matched on 721 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 721 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- The University of Texas Health Science Center, Houston · 732 trials · 20% recruiting
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
Sponsors near 20% open enrollment (± trial volume)
- University of California, Irvine · 20% recruiting · 368 trials
- Endeavor Health · 20% recruiting · 94 trials
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
Related
What to do with this University of Miami page
721 registered trials is a research-attention snapshot, not an endorsement of University of Miami or any single study.
- 145 of University of Miami's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Miami studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Miami pipeline card: 721 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.